ArticleCureus2026
Statin-Induced Necrotizing Autoimmune Myositis Presenting With Progressive Limb-Girdle Weakness Following Low-Dose Atorvastatin Use.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins are a mainstay in the prevention of cardiovascular disease and are associated with rare adverse effects, including statin-induced necrotizing autoimmune myositis (SINAM). This condition is characterized by progressive, symmetric, proximal muscle weakness and elevated creatine kinase (CK), persisting despite discontinuation of the statin, and is confirmed by the presence of anti-HMG-CoA reductase (HMGCR) antibodies. We present a case of a 72-year-old male who presented with three months of progressive limb-girdle weakness with chronic use of low-dose atorvastatin (10 mg). Our review of the literature suggests that this is the first documented case of SINAM in the setting of low-dose atorvastatin usage. Diagnosis was confirmed by anti-HMGCR antibodies. The patient was initially managed with corticosteroids and methotrexate but required escalation to intravenous immunoglobulin (IVIG), which led to functional improvement. This case underscores the need for high clinical suspicion for SINAM and highlights the importance of consideration for early aggressive immunosuppression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.